Us Congress 2023-2024 Regular Session

Us Congress House Bill HB4508

Introduced
7/10/23  
Refer
7/10/23  

Caption

Hidden Fee Disclosure Act

Impact

If enacted, HB 4508 would significantly impact how employer-sponsored health plans disclose financial information, particularly regarding pharmacy benefit management and various third-party administrative services. These amendments would enforce a requirement for health plans to itemize all fees, rebates, and any indirect compensation received in connection with the services provided. Such changes could lead to greater consumer awareness and, ultimately, more informed decisions regarding their healthcare choices. Similar legislation has been proposed in various forms in the past, highlighting the ongoing concern regarding transparency in healthcare costs and personnel compensation in the sector.

Summary

House Bill 4508, titled the 'Hidden Fee Disclosure Act of 2023', aims to amend the Employee Retirement Income Security Act of 1974 (ERISA) to enhance transparency regarding the fees and compensation structures associated with employer-sponsored health plans. This bill specifically requires covered service providers, including those managing pharmacy benefits, to provide detailed disclosures about their expected compensation, potential clawbacks, and other financial arrangements. By mandating annual reporting requirements, the legislation seeks to equip plan fiduciaries with better information to oversee the managed health services they provide, promoting accountability and aiming to mitigate hidden fees.

Sentiment

The sentiment surrounding HB 4508 appears to be cautiously optimistic among healthcare advocates who support the need for greater transparency in what has traditionally been an opaque area of employer-sponsored health services. Proponents argue that clearer disclosures will ultimately benefit employees and employers by allowing them to make better-informed choices regarding the management of their health plans. Conversely, there are apprehensions about the additional regulatory burden on service providers, with some stakeholders concerned that new disclosure requirements could lead to increased operational costs that might be passed down to employers and employees.

Contention

Key points of contention regarding HB 4508 include how its implementation will balance the need for transparency with the operational realities of healthcare providers. Critics argue that the disclosure requirements may create operational challenges or compliance burdens for smaller service providers who could struggle with the extensive data tracking necessary for compliance. Moreover, there is anticipation regarding how this legislation will interface with existing state laws and regulations governing health care, potentially leading to conflicts or overlaps that may confuse the implementation process.

Companion Bills

US HB5378

Related Lower Costs, More Transparency Act

Similar Bills

US HB2214

DRUG Act Delinking Revenue from Unfair Gouging Act

US HB9104

Access to Birth Control Act

US HB950

Saving Seniors Money on Prescriptions ActThis bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

US HB3162

Affordable and Safe Prescription Drug Importation Act of 2025

US SB882

Patients Before Middlemen Act

US SB644

Modernizing Opioid Treatment Access Act

US SB641

Safe and Affordable Drugs from Canada Act of 2025

US HB7535

Prescription Drug Supply Chain Pricing Transparency Act